Oct 20, 2022 Health Canada has approved SKYRIZI® (risankizumab) an intravenous and subcutaneous medication treatment for adults with moderately to severely active Crohn's Disease Learn moreEn savoir plus
Oct 13, 2022 Send an eCard to Friends or Family Members in Support of Crohn's and Colitis Canada Learn moreEn savoir plus
Sep 30, 2022 Today, September 30, Marks the Second National Day for Truth and Reconciliation in Canada Learn moreEn savoir plus
Sep 21, 2022 Crohn’s and Colitis Canada Awards 15 Post-Secondary Students a $5,000 Scholarship Through the 2022 AbbVie IBD Scholarship Program Learn moreEn savoir plus
Sep 15, 2022 Inflammatory bowel disease researchers from across the country receive vital funding that supports projects investigating Crohn’s disease and ulcerative colitis Learn moreEn savoir plus